Stoke Therapeutics Announces Completion of Enrollment of 162 Patients Into the Phase 3 EMPEROR Study of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome
Go back to Stoke Therapeutics Announces Completion of Enrollment of 162 Patients Into the Phase 3 EMPEROR Study of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome| BIOGEN IDEC Inc. (NASDAQ: BIIB) | Delayed: 213.43 -7.4 (3.35%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $220.83 | 52 Week High | $333.65 | |||
| Open | $215.45 | 52 Week Low | $223.02 | |||
| Day High | $217.28 | P/E | 27.33 | |||
| Day Low | $210.54 | EPS | $7.81 | |||
| Volume | 182,525 | |||||
| (NASDAQ: STOK) | Delayed: 30.09 +0.28 (0.94%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $29.81 | 52 Week High | $ | |||
| Open | $29.13 | 52 Week Low | $ | |||
| Day High | $30.42 | P/E | N/A | |||
| Day Low | $28.89 | EPS | $ | |||
| Volume | 127,523 | |||||
